Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

Curr Oncol · 2026 · PMC12939464 · PMID 41744876

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Though the OS data is still immature, there was a numerical trend in OS favouring ribociclib + NSAI (94.1% vs. 92.5%; HR 0.8; nominal p value 0.026).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.